Inhibition of NF-κB activation using cis-element 'decoy' of NF-κB binding site reduces neointimal formation in porcine balloon-injured coronary artery model

Gene Therapy

Volumn 10, Issue 4, 2003, Pages 356-364

  Yamasaki, K ^a   Asai, T ^a   Shimizu, M ^a   Aoki, M ^a   Hashiya, N ^a   Sakonjo, H ^b   Makino, H ^a   Kaneda, Y ^a   Ogihara, T ^a   Morishita, R ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Gene therapy; Inflammation; Remodeling; Restenosis; VSMC

Indexed keywords

DOUBLE STRANDED RNA; DRUG VEHICLE; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN P53; RAPAMYCIN; SYNAPTOTAGMIN; VASCULAR CELL ADHESION MOLECULE 1; OLIGODEOXYRIBONUCLEOTIDE;

ANGIOPLASTY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; CLINICAL STUDY; CONTROLLED STUDY; CORONARY ARTERY; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PROTEIN BINDING; FEASIBILITY STUDY; FLUORESCENCE; GENE INACTIVATION; GENE THERAPY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HYDROGEL; IN VIVO STUDY; INTRAVASCULAR ULTRASOUND; MACROPHAGE MIGRATION INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SWINE; VASCULAR LESION; ANIMAL; ARTICLE; BINDING SITE; CORONARY BLOOD VESSEL; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; GENETICS; INTIMA; METABOLISM; MINIPIG; PATHOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANIMALIA; SUIDAE; SUS SCROFA;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; BINDING SITES; CORONARY RESTENOSIS; CORONARY VESSELS; MALE; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; SWINE, MINIATURE; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0037289606     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301875     Document Type: Review

References (33)

1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-1438.
2. Lefkovits J, Topol EJ. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997; 40: 141-158.
3. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-κB and I-κB system in smooth muscle cells after rat arterial injury: induction of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1. Am J Pathol 1997; 151: 1085-1095.
4. Weber C et al. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-κB mobilization and induction of vascular cell adhesion molecule 1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb 1994; 14: 1665.
5. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. J Biol Chem 1995; 270: 933.
6. Yasukawa H et al. Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Circulation 1997; 95: 1515-1522.
7. Boucier T, Sukhova G, Libby P. The nuclear factor-κB signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997; 272: 15 817-15 824.
8. Brand K et al. Activated transcription factor nuclear factor-κB is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-1722.
9. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-κB and I-κB system in smooth muscle cells after rat arterial injury: induction of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1. Am J Pathol 1997; 151: 1085-1095.
10. Cercek B et al. Nuclear factor-κB activity and arterial response to balloon injury. Atherosclerosis 1997; 131: 59-66.
11. Bellas RE, Lee JS, Sonnenshein GE. Expression of a constitutive NF-κB-like activity is essentioal for proliferation of cultured bovine smooth muscle cells. J Clin Invest 1995; 96: 2521-2527.
12. Selzman CH et al. Liposomal delivery of purified inhibitory-κBα inhibits tumor necrosis factor-α-induced human vascular smooth muscle proliferation. Circ Res 1999; 84: 867-875.
13. Erl W et al. Nuclear factor-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res 1999; 84: 668-677.
14. Tomita N, Morishita R, Higaki J, Ogihara T. Strategy for functional inactivation of genes: a novel strategy for gene therapy and gene regulation analysis using transcriptional factor decoy oligonucleotides. Exp Nephrol 1997; 5: 429-434.
15. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82: 1023-1028.
16. Morishita R et al. In vivo transfection of cis element 'decoy' against nuclear factor-κB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-899.
17. Sawa Y et al. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFκB binding site: evidence for a role of NFκB in ischemic-reperfusion injury. Circulation 1997; 96:II-280-285.
18. Yoshimura S et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element "decoy" of nuclear factor-κB binding site as a novel molecular strategy. Gene Ther 2001;8:1635-1642.
19. Tomita N et al. In vivo administration of a nulear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 2000; 11: 1244-1252.
20. Tomita N et al. Transcription factor decoy for NFκB inhibits TNF-α-induced IL-6 and ICAM-1 expression in endothelial cells. J Hypertens 1998; 16: 993-1000.
21. Grimm S, Baeuerle PA. The inducible transcription factor NF-κB: structure-function relationship of its protein subunits. Biochem J 1993; 290: 297.
22. Collins T. Endothelial nuclear factor-κB and the initiation of atherosclerotic lesion. Lab Invest 1993; 68: 499.
23. Henkel T et al. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-κB subunit. Cell 1992; 68: 1121.
24. Henkel T et al. Rapid proteolysis of IκBα is necessary for activation of transcription factor NF-κB. Nature 1993; 365: 182-185.
25. Lawrence R et al. Vascular smooth muscle cells express a constitutive NF-κB-like activity. J Biol Chem 1994;269:28913-28918.
26. Bellas RE, Lee JS, Sonnenshein GE. Expression of a constitutive NF-κB-like activity is essential for proliferation of cultured bovine smooth muscle cells. J Clin Invest 1995; 96: 2521-2527.
27. Selzman CH et al. Liposomal delivery of purified inhibitory-κBα inhibits tumor necrosis factor-α-induced human vascular smooth muscle proliferation. Circ Res 1999; 84: 867-875.
28. Erl W et al. Nuclear factor-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res 1999; 84: 668-677.
29. Cercek B et al. Nuclear factor-κb activity and arterial response to balloon injury. Atherosclerosis 1997, 131: 59-66.
30. Wadgaonkar R et al. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J Biol Chem 1999; 274: 1879-1882.
31. Matsumoto K et al. Inhibition of neointima by ACE inhibitor in porcine coronary artery balloon injury model. Hypertension 2001; 37: 270-274.
32. Morishita R et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458-1464.
33. Ge J et al. Intravascular ultrasound imaging of arterial wall architecture. Echocardiography. 1992; 9: 475-483.